Acceleron Pharma has reported the preliminary results from the ACE-031 phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass. In addition to that the company also initiated a multiple dose phase 1 clinical trial for ACE-031.
Matthew Sherman, CMO at Acceleron, said: We are excited to share these encouraging results from our ACE-031 phase 1 single dose clinical trial at the World Muscle Society meeting next week.
Preliminary results show increases in lean body mass and muscle volume as well as positive effects on bone and fat. Based on the results of this phase 1 single dose clinical trial, we have initiated a multiple dose study of ACE-031 in healthy volunteers.”